← Leaderboards
Kevin M Patrie
Oxford Biomedical Research, Inc.
$1,281,262
Attributed
$1,281,262
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $617.4K · FY2011–14$1M$750K$500K$250K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$1,281,262 · 2
By mechanism
R44$1,163,577 · 1
R43$117,685 · 1
Top collaborators
No co-investigators on record.
Most similar at Oxford Biomedical Research, Inc.
Same institution · by research overlap
- Thomas R Brown$960,861
- Diane M Sasaki$197,185
Others in their field
Top investigators on “Family”
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$221,216,149
- David R. Weir · University Of Michigan At Ann Arbor$166,939,143
- Richard A Gibbs · Baylor College Of Medicine$137,231,081
- Sharon A Nachman · Johns Hopkins University$135,132,510
- George R Seage · Abt Associates, Inc.$128,485,281
Research focus
FamilyHepatotoxicityEnzymesFallsGlutathione S-TransferaseHalf-LifeDrug Or Chemical Tissue DistributionEarly DiagnosisAntibodiesExposure ToAnimal ModelFeasibility StudiesArchivesCellsCharacteristicsBiologicalCommercial ApplicationAcuteCross ReactivityDetectionBloodExhibitsDoseHuman Development
Grant awards (3)
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase$546,140
R44 · FY2014 · ES · contact PI
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase$617,437
R44 · FY2013 · ES · contact PI
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening$117,685
R43 · FY2011 · ES · contact PI